Form 8-K - Current report:
SEC Accession No. 0001104659-25-101390
Filing Date
2025-10-22
Accepted
2025-10-22 07:00:50
Documents
13
Period of Report
2025-10-17
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.06: Material Impairments
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2529188d1_8k.htm   iXBRL 8-K 42404
2 EXHIBIT 10.1 tm2529188d1_ex10-1.htm EX-10.1 37159
  Complete submission text file 0001104659-25-101390.txt   257837

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA nvax-20251017.xsd EX-101.SCH 3011
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE nvax-20251017_lab.xml EX-101.LAB 34239
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nvax-20251017_pre.xml EX-101.PRE 22356
15 EXTRACTED XBRL INSTANCE DOCUMENT tm2529188d1_8k_htm.xml XML 3558
Mailing Address 700 QUINCE ORCHARD ROAD GAITHERSBURG MD 20878
Business Address 700 QUINCE ORCHARD ROAD GAITHERSBURG MD 20878 240-268-2000
NOVAVAX INC (Filer) CIK: 0001000694 (see all company filings)

EIN.: 222816046 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-26770 | Film No.: 251408578
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)